Biodesix, Inc.
NASDAQ:BDSX · NASDAQ Global Market
+$2.04 today
Vol 0.13M · Avg 0.06M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
1430.6%
avg -62.4%
ROIC
-38.9%
avg -59.6%
ROA
-40.3%
avg -53.9%
Analysis
ROE is currently the strongest return metric at 1430.6% versus its period average of -62.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Scott Hutton | President, Chief Executive Officer & Director | $1.36M | — | 54 | $48,767.00 | 0.60% |
Kieran O'Kane | Chief Commercial Officer | $740,063.00 | — | 48 | $9,819.00 | 0.12% |
Robin Harper Cowie | Chief Financial Officer, Secretary & Treasurer | $694,772.00 | — | 46 | $16,231.00 | 0.20% |
Gary Anthony Pestano | Chief Scientific Officer | — | — | 58 | $10,359.00 | 0.13% |
Heinrich Roder D.Phil | Founder & Chief Technology Officer | — | — | — | — | — |
James R. Jett | Co-Chief Medical Officer | — | — | — | — | — |
Steven C. Springmeyer | Co-Chief Medical Officer | — | — | — | — | — |
Bobbi Coffin | Chief Growth Officer | — | — | — | — | — |
Jessica Olbricht | Senior Director of Human Resources | — | — | — | — | — |
Michael N. Kammer | Head of Radiomics | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$4.70M
Sells
25
$120,847.25
Net Sentiment
+$4.57M
Net buying
Most Active
SCHULER JACK W
7 transactions
1–10 of 32
Analysis
Insiders reported 7 buys worth $4.70M and 25 sells worth $120,847.25 over the last 12 months. That adds up to net buying of $4.57M. SCHULER JACK W was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +15.9% | +22.8% (8yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +15.9% over three years. Forward estimates point to Revenue at +22.8% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Mersana Therapeutics, Inc.
MRSN
$145.36M
OnKure Therapeutics, Inc.
NASDAQ:OKUR
$58.39M
Xilio Therapeutics, Inc.
NASDAQ:XLO
$58.15M
PDS Biotechnology Corporation
NASDAQ:PDSB
$50.97M
INmune Bio, Inc.
INMB
$36.16M
Aligos Therapeutics, Inc.
ALGS
$32.93M
Skye Bioscience, Inc.
SKYE
$25.03M
Wellgistics Health, Inc.
WGRX
$8.71M
VolitionRx Limited
VNRX
$8.55M
Inotiv, Inc.
NOTV
$2.79M
Who manages BDSX?
Biodesix, Inc. (BDSX) lists 10 active executives. The top listed executive is Robin Harper Cowie, Chief Financial Officer, Secretary & Treasurer.
Are BDSX insiders buying or selling?
Recent insider activity shows net buying of $9.73M.
Explore More
Continue the stock analysis
Jump to another research area for this company.